B+
Bull case
25%
Probability
Target price
$6.00
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
LRMR
Larimar TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Larimar has a visible regulatory and clinical path: the first rolling BLA module is submitted, confirmatory Phase 3 dosing is expected in Q3 2026, open-label data remain directionally supportive, and cash of $156.3 million was projected to fund operations into Q3 2027 [#SEC-8K-2026-08-04].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +3.0.
What can break
Clinical and regulatory approval are not assured despite FDA interaction and rolling BLA progress.
Momentum
43
Value
41
Sentiment
84
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.70 · Bull $6.00 · Bear $2.80Analysis 2026-08-17; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $14.30
Why
Momentum43 · Δ7d -37.0
Value41 · Δ7d -0.0
Sentiment84 · Δ7d +3.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +3.0.
Contradictions & invalidation
- • Clinical and regulatory approval are not assured despite FDA interaction and rolling BLA progress.
- • Confirmatory Phase 3 initiation and rolling BLA completion are execution-dependent and could slip.
- • Nomlabofusp remains dependent on regulatory acceptance and approval, confirmatory-study execution, and continued safety management.
Catalyst clock
2026-08-31
Q2 update showed an EPS beat, but post-print confirmation is limited
Lead driver: Sentiment · See AI snapshot
Momentum
43
9% active weight
Current posture
7d trendSoftening
Δ7d
-37.0
Δ21d
-40.0
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
84
62% active weight
Current posture
7d trendImproving
Δ7d
+3.0
Δ21d
+11.6
Why this grade
Composite grade A. Momentum 42.5 / Value 41.2 / Sentiment 84.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-17. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$4.70
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$2.80
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$448.77M
Beta
1.01
Shares Out
104.38M
P/E (TTM) · Derived
-1.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.48
Rev YoY
-
EPS YoY
-23.2%
Gross Margin
-
Op Margin
-
Net Debt
-$132.79M
Current Ratio
4.70
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data